Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'c7E3' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 86 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Paradiso-Hardy, FL; Madan, M; Radhakrishnan, S; Hurden, S; Cohen, EA
      Severe thrombocytopenia possibly related to readministration of eptifibatide

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    2. Neumann, FJ; Hochholzer, W; Pogatsa-Murray, G; Schomig, A; Gawaz, M
      Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    3. Coller, BS
      Anti-GPIIb/IIIa drugs: Current strategies and future directions

      THROMBOSIS AND HAEMOSTASIS
    4. Savi, P; Zamboni, G; Rescanieres, O; Herbert, JM
      Studies on the binding of H-3-SR121566, an inhibitor of Gp IIb-IIIa activation

      THROMBOSIS AND HAEMOSTASIS
    5. Zokai, K; Piazolo, L; Harenberg, J
      Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model

      SEMINARS IN THROMBOSIS AND HEMOSTASIS
    6. Huang, TC; Jordan, RE; Hantgan, RR; Alevriadou, BR
      Differential effects of c7E3 Fab on thrombus formation and rt-PA-mediated thrombolysis under flow conditions

      THROMBOSIS RESEARCH
    7. Quinn, MJ; Murphy, RT; Dooley, M; Foley, JB; Fitzgerald, DJ
      Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    8. Lages, B; Weiss, HJ
      Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb-IIIa inhibitors than by peptide and peptidomimetic inhibitors

      BRITISH JOURNAL OF HAEMATOLOGY
    9. Weber, AA; Schror, K
      Differential inhibition of adenosine diphosphate-versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics

      BLOOD
    10. Rozalski, M; Boncler, M; Golanski, J; Watala, C
      Effects of fibrinogen receptor antagonists GR144053F and aurintricarboxylic acid on platelet activation and degranulation

      BIOCHEMICAL PHARMACOLOGY
    11. Vahdat, B; Canavy, I; Fourcade, L; Garcia, E; Quilici, J; Bonnet, JL; Bory, M
      Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    12. Mathis, AS
      Newer antithrombotic strategies in the initial management of non-ST-Segment elevation acute coronary syndromes

      ANNALS OF PHARMACOTHERAPY
    13. Arjomand, H; Mascarenhas, DAN
      Combination of abciximab with primary stenting in patients with acute myocardial infarction: A community hospital experience

      JOURNAL OF INVASIVE CARDIOLOGY
    14. Kereiakes, DJ; Broderick, TM; Abbottsmith, C; Shimshak, TM
      Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: A new look at an old problem

      JOURNAL OF INVASIVE CARDIOLOGY
    15. Elmi, F; Peacock, T; Schiavone, J
      Isolated profound thrombocytopenia associated with clopidogrel

      JOURNAL OF INVASIVE CARDIOLOGY
    16. Stiegler, H; Fischer, Y; Steiner, S; Strauer, BE; Reinauer, H
      Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab

      ANNALS OF HEMATOLOGY
    17. Li, YF; Spencer, FA; Ball, S; Becker, RC
      Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    18. Talley, JD
      Pharmacology of GP IIb-IIIa platelet inhibitors, part IV

      JOURNAL OF INTERVENTIONAL CARDIOLOGY
    19. Roe, MT; Sapp, SK; Lincoff, AM
      Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

      CLEVELAND CLINIC JOURNAL OF MEDICINE
    20. Lincoff, AM; Califf, RM; Topol, EJ
      Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    21. Altman, R; Scazziota, A; Rouvier, J; Gonzalez, C
      Effect of sodium arachidonate on thrombin generation through platelet activation - Inhibitory effect of aspirin

      THROMBOSIS AND HAEMOSTASIS
    22. Hezard, N; Metz, D; Nazeyrollas, P; Droulle, C; Elaerts, J; Potron, G; Nguyen, P
      Use ct the PFA-100 (TM) apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents

      THROMBOSIS AND HAEMOSTASIS
    23. Reininger, AJ; Agneskirchner, J; Bode, PA; Spannagl, M; Wurzinger, LJ
      C7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-adsorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor - Results from patients with acute myocardial infarction and healthy controls

      THROMBOSIS AND HAEMOSTASIS
    24. Mukherjee, D; Moliterno, DJ
      Monitoring antiplatelet therapy - What is the best method?

      CLINICAL PHARMACOKINETICS
    25. Bhatt, DL; Topol, EJ
      Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    26. Kozak, M; Dovc, T; Rozman, P; Blinc, A
      A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximabin vitro

      WIENER KLINISCHE WOCHENSCHRIFT
    27. Himber, J; Burcklen, L; Steiner, B
      Effects of GP IIb/IIIa receptor antagonists on the activated clotting timeof heparinized blood

      BLOOD
    28. Silvestry, SC; Smith, PK
      Current status of cardiac surgery in the abciximab-treated patient

      ANNALS OF THORACIC SURGERY
    29. Lemmer, JH
      Clinical experience in coronary bypass surgery for abciximab-treated patients

      ANNALS OF THORACIC SURGERY
    30. Lemmer, JH; Metzdorff, MT; Krause, AH; Martin, MA; Okies, JE; Hill, JG
      Emergency coronary artery bypass graft surgery in abciximab-treated patients

      ANNALS OF THORACIC SURGERY
    31. Mascelli, MA; Kleiman, NS; Marciniak, SJ; Damaraju, L; Weisman, HF; Jordan, RE
      Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonistabciximab

      AMERICAN HEART JOURNAL
    32. Tcheng, JE
      Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment

      AMERICAN HEART JOURNAL
    33. Kereiakes, DJ; McDonald, M; Broderick, T; Roth, EM; Whang, DD; Martin, LH; Howard, WL; Schneider, J; Shimshak, T; Abbottsmith, CW
      Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use modelfor expediting care in acute coronary syndromes

      AMERICAN HEART JOURNAL
    34. Jordan, R; Mascelli, MA
      Pharmacological differentiation of GP IIb/IIIa inhibitors

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    35. Dunn, CJ; Foster, RH
      Abciximab - A pharmacoeconomic review of its use in percutaneous coronary revascularisation

      PHARMACOECONOMICS
    36. Sebastian, M; Makkar, R
      Glycoprotein IIb/IIIa receptor antagonists - Clinical pharmacology in cardiovascular diseases of aging

      DRUGS & AGING
    37. Vanscoy, GJ; Rihn, TL
      GP Ilb IIIa receptor inhibitors: Clinical and cost considerations in acutecoronary syndromes

      FORMULARY
    38. Greilich, PE; Alving, BM; Longnecker, D; Carr, ME; Whitten, CW; Chang, AS; Reid, TJ
      Near-site monitoring of the antiplatelet drug abciximab using the Hemodyneanalyzer and modified Thrombelastograph

      JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
    39. Gurbel, PA; O'Connor, CM; Cummings, CC; Serebruany, VL
      Clopidogrel: The future choice for preventing platelet activation during coronary stenting?

      PHARMACOLOGICAL RESEARCH
    40. O'Shea, C; Tcheng, JE
      Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction

      JOURNAL OF INVASIVE CARDIOLOGY
    41. Jayasundera, TG; Feldman, DN; Marmur, JD
      Tirofiban-induced coronary thrombolysis

      JOURNAL OF INVASIVE CARDIOLOGY
    42. Roe, MT; Moliterno, DJ
      Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: An emergency department perspective

      JOURNAL OF EMERGENCY MEDICINE
    43. Jubelirer, SJ; Koenig, BA; Bates, MC
      Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy

      AMERICAN JOURNAL OF HEMATOLOGY
    44. Gaede, A; Terres, W
      Therapy of the acute coronary syndrome. ASA, heparin, LMWH, hirudin and the GP-IIb/IIIa blockers

      HERZ
    45. Cohen, M; Ferguson, JJ; Harrington, RA
      Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: Applicability to the practice of medicine in the United States

      CLINICAL CARDIOLOGY
    46. Kleiman, NS
      A risk-benefit assessment of abciximab in angioplasty

      DRUG SAFETY
    47. Vorchheimer, DA; Badimon, JJ; Fuster, V
      Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    48. Harder, S; Kirchmaier, CM; Krzywanek, HJ; Westrup, D; Bae, JW; Breddin, HK
      Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects

      CIRCULATION
    49. Williamson, D; Giuliano, S; Jackson, SP
      Platelet adhesion receptors: novel targets for anti-thrombotic therapy

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE
    50. Kettner, SC; Panzer, OP; Kozek, SA; Seibt, FA; Stoiser, B; Kofler, J; Locker, GJ; Zimpfer, M
      Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery

      ANESTHESIA AND ANALGESIA
    51. Neumann, FJ; Schomig, A
      What's new in the treatment of unstable angina pectoris

      ANAESTHESIST
    52. Scarborough, RM
      Development of eptifibatide

      AMERICAN HEART JOURNAL
    53. Kleiman, NS
      Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors

      AMERICAN HEART JOURNAL
    54. Juran, NB
      Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy

      AMERICAN HEART JOURNAL
    55. Coller, BS
      Potential non-glycoprotein IIb IIIa effects of abciximab

      AMERICAN HEART JOURNAL
    56. Dangas, G; Marmur, JD; King, TE; De Leon, J; Sharma, SK; Vidhun, R; Feldman, D; Stoynov, MY; Badimon, JJ; Ambrose, JA
      Effects of platelet glycoprotein IIb IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention

      AMERICAN HEART JOURNAL
    57. DANGAS G; BADIMON JJ; COLLER BS; FALLON JT; SHARMA SK; HAYES RM; MERAJ P; AMBROSE JA; MARMUR JD
      ADMINISTRATION OF ABCIXIMAB DURING PERCUTANEOUS CORONARY INTERVENTIONREDUCES BOTH EX-VIVO PLATELET THROMBUS FORMATION AND FIBRIN DEPOSITION - IMPLICATIONS FOR A POTENTIAL ANTICOAGULANT EFFECT OF ABCIXIMAB

      Arteriosclerosis, thrombosis, and vascular biology
    58. CHONG PH
      GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS IN THE MANAGEMENT OF CARDIOVASCULAR-DISEASES/

      American journal of health-system pharmacy
    59. MEYER BJ
      ANTITHROMBOTIC DRUGS - INSIGHTS FROM CARDIOLOGY

      Cerebrovascular diseases
    60. DOBESH PP; LATHAM KA
      ADVANCING THE BATTLE AGAINST ACUTE ISCHEMIC SYNDROMES - A FOCUS ON THE GP IIB-IIIA INHIBITORS

      Pharmacotherapy
    61. Gibler, WB; Wilcox, RG; Bode, C; Castaigne, AD; Delooz, H; Elich, D; Fox, KAA; Kereiakes, DJ; Rupprecht, H; Topol, EJ
      Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting

      ANNALS OF EMERGENCY MEDICINE
    62. RONNER E; DYKUN Y; VANDENBRAND MJBM; VANDERWIEKEN LR; SIMOONS ML
      PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS - AN ASSET FOR TREATMENT OF UNSTABLE CORONARY SYNDROMES AND CORONARY INTERVENTION/

      European heart journal
    63. DOMANOVITS H; NIKFARDJAM M; JANATA K; HORNYKEWYCZ S; MAURER G; LAGGNER AN; HUBER K
      RESTORATION OF CORONARY BLOOD-FLOW BY SINGLE BOLUS INJECTION OF THE GPIIB IIIA RECEPTOR ANTAGONIST C7E3 FAB IN A PATIENT WITH ACUTE MYOCARDIAL-INFARCTION OF RECENT-ONSET/

      Clinical cardiology
    64. JOSEPH T; MARCO J; GREGORINI L
      ACUTE PROFOUND THROMBOCYTOPENIA AFTER ABCIXIMAB THERAPY DURING CORONARY ANGIOPLASTY

      Clinical cardiology
    65. MOUSA SA; FORSYTHE M; BOZARTH J; YOUSSEF A; WITYAK J; OLSON R; SIELECKI T
      XV454, A NOVEL NONPEPTIDE SMALL-MOLECULE PLATELET GIIB IIIA ANTAGONIST WITH COMPARABLE PLATELET ALPHA(IIB)BETA(3)-BINDING KINETICS TO C7E3/

      Journal of cardiovascular pharmacology
    66. BERKOMPAS DC
      ABCIXIMAB COMBINED WITH ANGIOPLASTY IN A PATIENT WITH RENAL-ARTERY STENT SUBACUTE THROMBOSIS

      Catheterization and cardiovascular diagnosis
    67. HAUDE M; ALTMANN C; EICK B; LIU FQ; SCHWIPPERT B; TSCHOPE D; ERBEL R
      ANALYSIS OF VESSEL WALL MORPHOLOGY, BLOOD-FLOW VELOCITY, AND THE HEMOSTATIC SYSTEM IN A PATIENT WITH A LARGE INTRACORONARY THROMBUS

      Catheterization and cardiovascular diagnosis
    68. PEDICORD DL; THOMAS BE; MOUSA SA; DICKER IB
      GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS INHIBIT THE DEVELOPMENT OFPLATELET PROCOAGULANT ACTIVITY/

      Thrombosis research
    69. Neumann, FJ; Schomig, A
      News on the treatment of unstable angina pectoris

      INTERNIST
    70. FOSTER RH; WISEMAN LR
      ABCIXIMAB - AN UPDATED REVIEW OF ITS USE IN ISCHEMIC-HEART-DISEASE

      Drugs
    71. POPMA JJ; WEITZ J; BITTL JA; OHMAN M; KUNTZ RE; LANSKY AJ; KING SB
      ANTITHROMBOTIC THERAPY IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY

      Chest
    72. TAM SH; SASSOLI PM; JORDAN RE; NAKADA MT
      ABCIXIMAB (REOPRO, CHIMERIC 7E3 FAB) DEMONSTRATES EQUIVALENT AFFINITYAND FUNCTIONAL BLOCKADE OF GLYCOPROTEIN IIB IIIA AND ALPHA(V)BETA(3) INTEGRINS/

      Circulation
    73. MASCELLI MA; LANCE ET; DAMARAJU L; WAGNER CL; WEISMAN HF; JORDAN RE
      PHARMACODYNAMIC PROFILE OF SHORT-TERM ABCIXIMAB TREATMENT DEMONSTRATES PROLONGED PLATELET INHIBITION WITH GRADUAL RECOVERY FROM GP IIB IIIARECEPTOR BLOCKADE/

      Circulation
    74. ALVAREZ JM; HARPER RW; PEVERILL RE
      EMERGENCY CORONARY-ARTERY BYPASS-GRAFTING (CABG) AFTER FAILED CORONARY-ARTERY INTERVENTION - CAUTION REGARDING THE COMBINED USE OF ASPIRIN,TICLOPIDINE AND ABCIXIMAB

      Australian and New Zealand Journal of Medicine
    75. LINCOFF AM
      TRIALS OF PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONISTS DURING PERCUTANEOUS CORONARY REVASCULARIZATION/

      The American journal of cardiology
    76. KLEIMAN NS; LINCOFF AM; OHMAN EM; HARRINGTON RA
      GLYCOPROTEIN IIB IIIA INHIBITORS IN ACUTE CORONARY SYNDROMES - PATHOPHYSIOLOGIC FOUNDATION AND CLINICAL FINDINGS/

      The American heart journal
    77. BERKOWITZ SD; FRELINGER AL; HILLMAN RS
      PROGRESS IN POINT-OF-CARE LABORATORY TESTING FOR ASSESSING PLATELET-FUNCTION

      The American heart journal
    78. KAMAT SG; TURNER NA; KONSTANTOPOULOS K; HELLUMS JD; MCINTIRE LV; KLEIMAN NS; MOAKE JL
      EFFECTS OF INTEGRELIN ON PLATELET-FUNCTION IN FLOW MODELS OF ARTERIALTHROMBOSIS

      Journal of cardiovascular pharmacology
    79. MURDOCK DK; LOGEMANN T; HOFFMANN MT; OLSON KJ; ENGELMEIER RS
      CORONARY-ARTERY STENTING FOR SUBOPTIMAL PTCA RESULTS IN ACUTE MYOCARDIAL-INFARCTION IN PATIENTS TREATED WITH ABCIXIMAB - EARLY AND 6-MONTH OUTCOME

      Catheterization and cardiovascular diagnosis
    80. AMMAR T; SCUDDER LE; COLLER BS
      IN-VITRO EFFECTS OF THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTAGONIST C7E3 FAB ON THE ACTIVATED CLOTTING TIME/

      Circulation
    81. ADGEY AAJ
      BLEEDING COMPLICATIONS WITH NEW ANTITHROMBOTICS USED IN ISCHEMIC-HEART-DISEASE

      Haemostasis
    82. SCHULTZ RD; HEUSER RR; HATLER C; FREY D
      USE OF C7E3 FAB IN CONJUNCTION WITH PRIMARY CORONARY STENTING FOR ACUTE MYOCARDIAL INFARCTIONS COMPLICATED BY CARDIOGENIC-SHOCK

      Catheterization and cardiovascular diagnosis
    83. MACHNIG T; POTRATZ J; SHEIKHZADEH A
      PREVENTION OF THROMBOTIC COMPLICATIONS IN INTERNATIONAL CARDIOLOGY - A REVIEW OF NEW PHARMACOLOGICAL APPROACHES

      Herz, Kreislauf
    84. REVERTER JC; BEGUIN S; KESSELS H; KUMAR R; HEMKER HC; COLLER BS
      INHIBITION OF PLATELET-MEDIATED, TISSUE FACTOR-INDUCED THROMBIN GENERATION BY THE MOUSE HUMAN CHIMERIC 7E3 ANTIBODY - POTENTIAL IMPLICATIONS FOR THE EFFECT OF C7E3 FAB TREATMENT ON ACUTE THROMBOSIS AND CLINICAL RESTENOSIS/

      The Journal of clinical investigation
    85. VANHOUT BA; SIMOONS ML
      COSTS AND EFFECTS OF C7E3 IN HIGH-RISK PTCA PATIENTS - AN INDIRECT ANALYSIS FOR THE NETHERLANDS

      European heart journal
    86. COUTRE S; LEUNG L
      NOVEL ANTITHROMBOTIC THERAPEUTICS TARGETED AGAINST PLATELET GLYCOPROTEIN IIB IIIA/

      Annual review of medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/06/20 alle ore 22:25:50